Application of levofloxacine in the second phase of sequential therapy regimen for Helicobacter pylori eradication: Is it a good choice?

Minerva Medica

Volumn 102, Issue 3, 2011, Pages 171-176

  Guzelbulut F ^a   Sezikli, M ^a   Akkan Cetinkaya Z ^b   Erhan Altunoz M ^a   Gunes P ^a   Duzgun S ^a   Ovunc Kurdas O ^a  

^a HAYDARPASA NUMUNE EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b Kocaeli Derince Education and Research Hospital   (Turkey)

Author keywords

Gastroenterology; Helicobacter pylori; Ofloxacin

Indexed keywords

AMOXICILLIN; LANSOPRAZOLE; LEVOFLOXACIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DRUG CHOICE; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MALE; TREATMENT OUTCOME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DYSPEPSIA; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; OFLOXACIN; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79960993456     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Marshall BJ. The 1995 Albert Lasker Medical Research Award. Helicobacter pylori. The etiologic agent for peptic ulcer. JAMA 1995;274:1064-6.
2. Parsonnet J, Hansen S, Rodriguez L, Gelb AB, Warnke RA, Jellum E et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med 1994;330:1267-71. (Pubitemid 24129959)
3. Blaser MJ, Berg DE. Helicobacter pylori genetic diversity and risk of human disease. J Clin Invest 2001;107:767-73. (Pubitemid 32274024)
4. Wilkinson M. Helicobacter pylori: an overview. Br J Biomed Sci 2001;58:59-60. (Pubitemid 32566032)
5. Akin L, Tezcan S, Hasçelik G, Çakir B. Seroprevalence and some correlates of Helicobacter pylori at adult ages in Gülveren Health District, Ankara, Turkey. Epidemiol Infect 2004;132:847-56. (Pubitemid 39307341)
6. Özden A, Dumlu Dönderici Ö, Çetinkaya H, Soylu K, Özkan H. Helicobacter pylori infeksiyonunun ülkemizde seroepidemiyolojisi (Helicobacter pylori seroepidemiology in Turkey). Gastroenteroloji 1992;3:664-8.
7. Karaaslan H, Bektaş M, Soykan Bozkaya H, Bahar K, Özden A. Türkiyede gönüllü kan donörlerinde Helicobacter pylori seroprevelansi (Helicobacter pylori seroprevalence in blood donors in Turkey).Turk J Gastroenterol 2003;(Suppl) B.03/1.
8. Kadayifçi A. Büyükhatipoǧlu H, Koruk M et al. Türkiye'de H. Pilori eradikasyonunda PPI, amoksisilin ve klaritromisin tedavisinin etkinliǧi: meta-analiz. Turk J Gastroenterol 2004;15(Suppl):5.
9. Zullo A, Vaira D, Vakil N, Hassan C, Gatta L, Ricci C et al. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther 2003;17:719-26.
10. Tong JL, Ran ZH, Shen J, Xiao SD. Sequential therapy vs. standard triple therapies for Helicobacter pylori infection: a meta-analysis. J Clin Pharm Ther 2009;34:41-53.
11. Uygun A, Kadayifci A, Yesilova Z, Safali M, Ilgan S, Karaeren N. Comparison of sequential and standard triple-drug regimen for helicobacter pylori eradication: a 14-day, open-label, randomized, prospective, parallel-arm study in adult patients with nonulcer dyspepsia. Clin Ther 2008;30:528-34 (Pubitemid 351483928)
12. Sezgin O, Altintaş E, Nayir E, Uçbilek E. A pilot study evaluating sequential administration of a PPI-amoxicillin followed by a PPI-metronidazole-tetracycline in Turkey. Helicobacter 2007;12:629-32. (Pubitemid 350139030)
13. Cetinkaya ZA, Sezikli M, Güzelbulut F, Coşgun S, Düzgün S, Kurdaş OO. Comparison of the efficacy of the two tetracycline-containing sequential therapy regimens for the eradication of Helicobacter pylori: 5 days versus 14 days amoxicillin. Helicobacter 2010;15:143-7.
14. Aydin A, Oruc N, Turan I, Ozutemiz O, Tuncyurek M, Musoglu A. The modified sequential treatment regimen containing levofloxacin for Helicobacter pylori eradication in Turkey. Helicobacter 2009;14:520-4.
15. Yaşar B, Şenateş E, Coşgun S, Altunöz ME, Yapali S, Sezikli M et al. Helicobacter pilori pozitif non ülser dispepsili hastalarda standart üçlü ted rejimi ile levofloksasin bazli üçlü ted rejiminin eradikasyon oranlarinin karşilaştirilmasi (abstract). Turk J Gastroenterol 2009;20(Suppl 1):23.
16. Nista EC, Candelli M, Zocco MA, Cremonini F, Ojetti V Finizio R et al. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication. Am J Gastroenterol 2006;101:1985-90. (Pubitemid 44337620)
17. Gisbert JP, Bermejo F, Castro-Fernandez M, Tomas A, Barrio J, Bory F et al. Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients. Am J Gastroenterol 2008;10:71-6.
18. Güliter S, Keleş H, Ozkurt ZN, Cengiz DU, Kolukisa E. Can lansoprazole, amoxicillin, and clarithromycin combination still be used as a first-line therapy for eradication of helicobacter pylori? Turk J Gastroenterol 2005;16:29-33.
19. Simsek H, Balaban YH, Gunes DD, Hasçelik G, Özarlan E, Tatar G. Alarming clarithromycin resistance of Helicobacter pylori in Turkish population. Helicobacter 2005;10:360-1.
20. Göral V, Zeyrek FH, Gül K. Antibiotic resistance in helicobacter pylori infection. T Klin Gastroenterohepatol 2000;1:87-92
21. Cheng H, Hu FL, Zhang GX, Shi RH, Du YQ, Li ZS et al. Levofloxacin-based triple therapy for first-line Helicobacter pylori eradication treatment: a multicentral, randomized, controlled clinical study. Zhonghua Yi Xue Za Zhi 2010;90:79-82.
22. Zhang ZF, Zhao G, Liu LN. Effectiveness and safety of proton pump inhibitor and levofloxacin based first-line triple therapy in the eradication of Helicobacter pylori: a meta-analysis. Zhonghua Yi Xue Za Zhi 2008;88:2722-5.
23. Castro-Fernández M, Lamas E, Pérez-Pastor A, Pabón M, Aparcero R, Vargas-Romero J et al. Efficacy of triple therapy with a proton pump inhibitor, levofloxacin, and amoxicillin as first-line treatment to eradicate Helicobacter pylori. Rev Esp Enferm Dig 2009;101:395-402.
24. Seven G, Çinar K, Yakut M, İdilman R, Kabaçam G, Özden A. Naiv helicobacter pilori eradikasyonunda yeni rejimler. (abstract). Turk J Gastroenterol 2009;20(Suppl 1):23.
25. Polat Z, Uygun A, Kilciler G, Erçin CN, Kantarcioǧlu M, Kara M et al. Birinci basamak helicobacter pilori tedavisinde üç farkli tedavi protokolünün karşilaştirilmasi (abstract). Turk J Gastroenterol 2009;20(Suppl 1):21.
26. Sezgin O, Altintaş E, Nayir E, Uçbilek E. A pilot study evaluating sequential administration of a PPI-amoxicillin followed by a PPI-metronidazole-tetracycline in Turkey. Helicobacter 2007;12:629-32. (Pubitemid 350139030)
27. Molina-Infante J, Perez-Gallardo B, Fernandez-Bermejo M, Hernandez-Alonso M, Vinagre G, Dueñas C et al. Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther 2010;20.
28. Krystallis C, Kamberoglu D, Pistiolas D, Anifanti C, Koutsoumbas A, Doulgeroglou V et al. A new second-line sequential regimen for helicobacter pylori eradication based on levofloxacin: A pilot study. Dis Sci 2010;16.